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ABSTRACT
Background There is concern that blood pressure 
(BP) lowering in acute stroke may compromise cerebral 
perfusion and worsen outcome in the presence of carotid 
stenosis. We assessed the effect of glyceryl trinitrate 
(GTN) in patients with carotid stenosis using data from the 
Efficacy of Nitric Oxide in Stroke (ENOS) Trial.
Methods ENOS randomised 4011 patients with acute 
stroke and raised systolic BP (140–220 mm Hg) to 
transdermal GTN or no GTN within 48 hours of onset. Those 
on prestroke antihypertensives were also randomised to 
stop or continue their medication for 7 days. The primary 
outcome was the modified Rankin Scale (mRS) at day 90. 
Ipsilateral carotid stenosis was split: <30%; 30–<50%; 
50–<70%; ≥70%. Data are ORs with 95% CIs adjusted for 
baseline prognostic factors.
Results 2023 (60.5%) ischaemic stroke participants had 
carotid imaging. As compared with <30%, ≥70% ipsilateral 
stenosis was associated with an unfavourable shift 
in mRS (worse outcome) at 90 days (OR 1.88, 95% CI 
1.44 to 2.44, p<0.001). Those with ≥70% stenosis who 
received GTN versus no GTN had a favourable shift in mRS 
(OR 0.56, 95% CI 0.34 to 0.93, p=0.024). In those with 
50–<70% stenosis, continuing versus stopping prestroke 
antihypertensives was associated with worse disability, 
mood, quality of life and cognition at 90 days. Clinical 
outcomes did not differ across bilateral stenosis groups.
Conclusions Following ischaemic stroke, severe 
ipsilateral carotid stenosis is associated with worse 
functional outcome at 90 days. GTN appears safe in 
ipsilateral or bilateral carotid stenosis, and might improve 
outcome in severe ipsilateral carotid stenosis.
INTRODUCTION
Blood pressure (BP) is elevated in 75% of 
patients presenting with acute ischaemic 
stroke1 and is associated independently with 
poor clinical outcomes.2 3 Lowering elevated 
BP appears safe in acute ischaemic stroke, but 
has failed to show clinical benefit.4 There is 
a specific concern regarding BP lowering in 
the 15% of patients with significant carotid 
stenosis in whom cerebral perfusion may be 
compromised and where reducing BP might 
extend the ischaemic core and potentially 
worsen outcome.5 Data on BP reduction in 
severe ipsilateral or bilateral carotid stenosis 
are limited, although a meta-analysis found 
that lower BP was associated with an increased 
rate of stroke recurrence in bilateral carotid 
stenosis.6 In the ultra-acute prehospital and 
acute hospital situation, information on 
carotid stenosis is often not available and it 
is unclear whether BP lowering is safe in this 
group of patients with stroke.
The Efficacy of Nitric Oxide in Stroke 
(ENOS) Trial assessed the safety and efficacy 
of transdermal glyceryl trinitrate (GTN) and 
of continuing prestroke antihypertensives in 
4011 patients with acute stroke.7 Although 
GTN lowered BP by 7/3.5 mm Hg at day 1, 
GTN did not influence functional outcome 
at 90 days.7 However, when administered 
within 6 hours of stroke onset GTN improved 
several clinical outcomes.8 The aim of the 
current preplanned substudy9 was to assess 
the safety and efficacy of BP lowering on clin-
ical outcomes in patients with acute ischaemic 
stroke and carotid stenosis.
METHODS
Details pertaining to the ENOS trial protocol, 
statistical analysis plan, baseline charac-
teristics and main trial results have been 
published.8 10–12 In summary, the ENOS Trial 
recruited 4011 patients with acute stroke 
within 48 hours of onset with high systolic 
BP (140–220 mm Hg) and randomised them 
to GTN 5 mg patch or no patch for 7 days. 
Those participants taking antihypertensive 
medication prior to their index event were 
also randomised to continue or stop these 
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drugs for 7 days. Known carotid stenosis was not an exclu-
sion criterion. Written consent to participate was given by 
patients or relatives/carers in those who lacked capacity. 
The ENOS Trial was registered (ISRCTN99414122).
Patient and public involvement
Patients and public were not involved in the development 
of this preplanned secondary analysis of the ENOS trial.
Carotid stenosis
Clinical information on carotid stenosis was collected by 
investigators during the participant’s index event admis-
sion. Clinical imaging using either carotid Doppler, MR 
angiography or CT angiography was performed as per 
local protocol. Investigators entered the % of stenosis of 
both left and right internal carotid arteries using North 
American Symptomatic Carotid Endarterectomy Trial 
(NASCET) criteria where available (online supplemen-
tary material).13 Data were checked and validated but no 
central adjudication of carotid imaging was performed.
Participants who had a final diagnosis of ischaemic 
stroke and who had carotid data available were included 
in this substudy. Grades of carotid stenosis were defined 
as follows:
 ► Unilateral carotid stenosis ipsilateral to the symp-
tomatic hemisphere:13 <30%, 30–<50%, 50–<70%, 
≥70%.
 ► Bilateral carotid stenosis (% for both carotid arteries): 
<30%, 30–<50%, ≥50%.
Haemodynamic measures
BP and heart rate were measured peripherally at base-
line (three measurements) and on days 1–7 (two meas-
urements/day), using validated automated equipment 
(Omron 705 CP).14
Clinical outcomes
The primary outcome in ENOS was functional outcome 
measured using the modified Rankin Scale15 (mRS, a 
seven-level categorical scale where 0=independent and 
6=dead) at 90 days. Day 90 secondary outcomes included 
disability (Barthel Index),16 mood (Zung Depression 
Scale),17 quality of life (health utility status calculated 
using the European Quality of Life 5-dimensions three 
levels version, and Visual Analogue Scale)18 and cogni-
tion (telephone mini-mental state examination,19 modi-
fied Telephone Interview for Cognition Scale [TICS-M]20 
and verbal fluency). Patients who had died by day 90 were 
assigned a worst score for the outcomes. Safety data were 
collected on all-cause mortality at day 90, early neurolog-
ical deterioration (a minimum 5-point reduction overall 
or >2 points reduction in the consciousness domain from 
baseline to day 7 on the Scandinavian Stroke Scale [SSS]), 
symptomatic hypotension, hypertension or headache 
by day 7. The National Institute of Health Stroke Scale 
(NIHSS) was calculated from SSS.21 Day 90 outcomes 
were recorded by trained blinded assessors via telephone 
at national coordinating centres.
Statistical analysis
In line with the ENOS Trial statistical analysis plan 
and statistical analyses performed in the primary 
publication, intention-to-treat analysis of data was 
carried out.11 Data are number (%), median [IQR] or 
mean (SD). Baseline characteristics between grades 
of carotid stenoses were assessed using the χ2test for 
categorical variables and one-way analysis of variance 
for continuous variables.
Associations between carotid stenosis grades and 
outcomes were assessed using multiple linear regres-
sion, ordinal logistic regression or binary logistic 
regression with adjustment for baseline prognostic 
covariates including age, sex, baseline mRS score, 
history of previous stroke, history of diabetes mellitus, 
total anterior circulation stroke, nitrate use, baseline 
SSS, thrombolysis, feeding status, time to randomisa-
tion and baseline systolic BP. Analyses involving the 
whole population were also adjusted for treatment 
allocation. Associations between BP change from base-
line to day 1 and outcome across degrees of carotid 
stenosis were assessed per 10 mm Hg reduction in BP. 
Interaction p values were obtained by adding an inter-
action term to statistical models. Data are mean differ-
ence or OR and associated 95% CIs, with significance 
defined as p≤0.05. Analyses were performed using 
SPSS V.24 (Chicago, Illinois, USA).
RESULTS
Of 4011 participants, 2023 (50.4%) had a final diagnosis 
of ischaemic stroke and carotid imaging data (GTN 1002 
vs no GTN 1021, table 1). One thousand three hundred 
and nineteen (32.9%) patients with ischaemic stroke did 
not have carotid imaging, typically those with more severe 
stroke (carotid imaging: SSS 36.6 [12.4], no imaging: SSS 
30.6 [13.7], p<0.001); there was no relationship between 
country of enrolment and whether carotid imaging was 
performed (data not shown). Of 2023 participants with 
carotid data, 148 (7.3%) had 50–<70% ipsilateral stenosis, 
213 (10.5%) had ≥70% ipsilateral stenosis and 97 (4.8%) 
had ≥50% bilateral stenosis. Age and rates of treated 
hypertension, diabetes mellitus, atrial fibrillation, history 
of transient ischaemic attack, ischaemic heart disease 
and peripheral arterial disease differed across grades of 
ipsilateral carotid stenosis. Those with higher degrees of 
ipsilateral carotid stenosis were more likely to be male, 
current smokers, have more severe strokes with higher 
NIHSS and lower Glasgow Coma Scale Scores, fewer 
cardioembolic and small vessel disease-related strokes, 
and more received thrombolysis treatment (table 1). As 
compared with patients with carotid imaging data, those 
without had a worse functional outcome at day 90: mRS 4 
[3] versus 3 [3], (OR 1.76, 95% CI 1.54 to 2.01, p<0.001).
Relationship between carotid stenosis and outcome
Across all patients and as compared with participants 
with <30% ipsilateral stenosis, those with ≥70% stenosis 
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had an unfavourable shift in mRS (worse outcome) at 
day 90 (OR 1.88, 95% CI 1.44 to 2.44, p<0.001, table 2, 
figure 1); significant associations with worse disa-
bility and quality of life, more depression and poorer 
cognitive scores were also seen. In addition, those 
with ≥70% stenosis had an increased rate of recurrent 
ischaemic stroke, clinical deterioration, neurolog-
ical deterioration, and higher NIHSS Scores at day 7 
(online supplementary table 1).
Effects of GTN versus no GTN
Those with ≥70% ipsilateral stenosis who were 
randomised to GTN had a significant shift in mRS to 
less death or dependency at 90 days (OR 0.56, 95% CI 
0.34 to 0.93, p=0.024) (table 3, figure 2). However, 
GTN did not influence mRS across the other carotid 
stenosis groups, although there were higher cognitive 
scores at day 90 in those with 50–<70% stenosis but 
not in other stenosis groups. Headache, a recognised 
side effect of GTN, was more common in those with 
≥70% stenosis who were randomised to GTN; non-sig-
nificant increases in headache with GTN were also 
reported in the other carotid stenosis groups (online 
supplementary table 2).
Effects of continuing versus stopping prestroke 
antihypertensives
In those with 50–<70% ipsilateral stenosis, continuing 
prestroke antihypertensives was associated with more 
depression, worse disability and quality of life, and poorer 
cognitive score (TICS-M) at day 90 compared with stop-
ping prestroke antihypertensives, independent of GTN 
allocation. No effect on mRS was seen nor were these 
effects replicated in those with more severe (≥70%) ipsi-
lateral stenosis (table 3).
Bilateral carotid stenosis
Only 97/2023 (4.8%) had ≥50% bilateral carotid stenosis. 
There were no significant associations across degrees of 
bilateral carotid stenosis with clinical outcome measures 
at either 7 or 90 days (online supplementary table 4). 
Neither GTN nor continuing prestroke antihypertensives 
influenced outcome in participants with bilateral carotid 
stenosis (data not shown).
BP change and carotid stenosis
The largest fall in BP was seen from baseline to day 1 in 
those randomised to GTN versus no GTN (7/3 mm Hg 
overall) and did not significantly differ across degrees 
of ipsilateral (online supplementary table 2, interaction 
p=0.22) or bilateral carotid stenosis (interaction p=0.19). 
When assessed across degrees of ipsilateral carotid 
stenosis, change in BP from baseline to day 1 did not 
influence mRS at day 90 (online supplementary table 5). 
There were no significant interactions between treatment 
with GTN or continuing prestroke antihypertensives in 
relation to BP change and outcome. Similarly, across 
degrees of bilateral carotid stenosis, change in BP from 
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Figure 1  mRS at day 90 <30% vs ≥70% ipsilateral stenosis. 
mRS, modified Rankin Scale.
Ta
bl
e 
3 
Fu
nc
tio
na
l o
ut
co
m
e 
an
d 
de
at
h 
at
 d
ay
 9
0 
by
 ra
nd
om
is
ed
 tr
ea
tm
en
t b
y 
de
gr
ee
 o
f i
ps
ila
te
ra
l c
ar
ot
id
 s
te
no
si
s
S
te
no
si
s 
30
–<
50
%
S
te
no
si
s 
50
–<
70
%
S
te
no
si
s 
≥7
0%
G
TN
N
o 
G
TN
O
R
 (9
5%
 C
I)
P
 v
al
ue
G
TN
N
o 
G
TN
O
R
 (9
5%
 C
I)
P
 v
al
ue
G
TN
N
o 
G
TN
O
R
 (9
5%
 C
I)
P
 v
al
ue
N
um
be
r o
f 
pa
rt
ic
ip
an
ts
10
2
12
2
–
– 
77
71
– 
– 
94
11
9
– 
– 
m
R
S
 (/
6)
*
2 
[3
]
3 
[2
]
0.
77
 (0
.4
7 
to
 1
.2
7)
0.
31
3 
[2
]
3 
[2
]
0.
71
 (0
.3
9 
to
 1
.3
1)
0.
28
3 
[2
]
4 
[2
]
0.
56
 (0
.3
4 
to
 0
.9
3)
0.
02
4
D
ea
th
 (%
)
7 
(6
.9
)
14
 (1
1.
5)
0.
43
 (0
.1
4 
to
 1
.3
2)
0.
14
3 
(3
.9
)
8 
(1
1.
3)
0.
18
 (0
.0
3 
to
 1
.0
3)
0.
05
4
9 
(9
.7
)
16
 (1
3.
4)
0.
63
 (0
.2
3 
to
 1
.7
5)
0.
37
C
on
tin
ue
 
S
to
p 
C
on
tin
ue
S
to
p
C
on
tin
ue
S
to
p
N
um
be
r o
f
pa
rt
ic
ip
an
ts
65
68
– 
– 
52
47
– 
– 
57
57
– 
– 
 
 m
R
S
 (/
6)
*
2 
[3
]
2.
5 
[3
]
0.
93
 (0
.4
8 
to
 1
.8
0)
0.
82
3 
[2
]
3 
[2
]
1.
92
 (0
.8
6 
to
 4
.2
7)
0.
11
4 
[3
]
4 
[3
]
1.
46
 (0
.7
3 
to
 2
.9
3)
0.
29
 
 D
ea
th
 (%
)
9 
(1
3.
8)
7 
(1
0.
3)
1.
59
 (0
.4
2 
to
 6
.0
1)
0.
49
6 
(1
1.
5)
1 
(2
.1
)
81
.0
0 
(1
.0
8 
to
 6
09
3.
98
)
0.
04
6
12
 (2
1.
4)
6 
(1
0.
5)
3.
11
 (0
.8
5 
to
 1
1.
44
)
0.
09
baseline to day 1 did not influence mRS at day 90 (online 
supplementary table 6).
DISCUSSION
In this preplanned ENOS substudy,9 taking all patients 
irrespective of treatment allocation, the presence of 
severe (≥70%) ipsilateral symptomatic carotid stenosis 
was associated with unfavourable clinical outcomes both 
early and late after acute stroke. However, treatment with 
GTN versus no GTN was associated with a significant shift 
to less death or dependency at 90 days in those partic-
ipants with ≥70% ipsilateral stenosis. Continuing versus 
stopping prestroke antihypertensives was associated with 
worse secondary outcomes in those with 50–<70% ipsi-
lateral stenosis. Modest BP lowering was safe in patients 
with acute stroke in the context of unilateral and bilateral 
carotid stenosis.
It has long been established that higher degrees of 
symptomatic carotid stenosis are associated with early 
stroke recurrence and subsequent dependency after 
minor stroke and transient ischaemic attack; carotid 
endarterectomy is therefore recommended.22 This 
dataset suggests that patients with more severe strokes 
with large artery disease who may not have been 
eligible for carotid revascularisation have both poor 
early and late clinical outcomes as expected. These 
findings are likely to be even stronger in clinical prac-
tice as the 32.9% patients with ischaemic stroke who 
did not have carotid imaging had more severe strokes 
and therefore worse clinical outcome than those with 
imaging.
Although pathophysiological data have demon-
strated dysfunctional cerebral autoregulation in 
severe carotid stenosis,23–25 and cerebral blood flow 
can become dependent on systemic BP,5 there are 
limited prospective data assessing BP lowering in 
acute stroke with carotid stenosis. Previous blinded 
analysis of ENOS performed during recruitment 
revealed that BP lowering in the context of carotid 
stenosis was safe.9 We have reinforced that finding 
here with no evidence to suggest modest BP lowering 
 on 25 M
arch 2019 by guest. Protected by copyright.
http://svn.bm
j.com
/
Stroke Vasc Neurol: first published as 10.1136/svn-2019-000232 on 19 M
arch 2019. Downloaded from
 
 33Appleton JP, et al. Stroke and Vascular Neurology 2019;4:e000232. doi:10.1136/svn-2019-000232
Open access
Figure 2  mRS at day 90 in those with ≥70% ipsilateral 
stenosis GTN versus no GTN. GTN, glyceryl trinitrate; mRS, 
modified Rankin Scale.
is associated with stroke recurrence or other poor 
outcomes. A post hoc analysis of the Scandinavian 
Candesartan Acute Stroke Trial (SCAST) found no 
clear evidence to suggest that BP lowering was detri-
mental in patients with carotid stenosis, but there 
were non-significant tendencies towards increased 
stroke progression and poor functional outcome 
with candesartan.26 As in the present substudy, the 
observed BP lowering effect in SCAST was modest 
(5/2 mm Hg) and therefore differing drug class 
effects may explain the differences observed between 
the present analysis and SCAST. Further, continuing 
prestroke antihypertensives in those with modest ipsi-
lateral carotid stenosis (50–<70%) was associated with 
poorer outcomes across several secondary domains, 
but not in those with ≥70% ipsilateral stenosis. This 
may be due to those with modest stenosis having 
greater baseline comorbidity (higher mRS, more 
hypertension, diabetes, previous stroke, ischaemic 
heart disease and hyperlipidaemia) than those with 
≥70% stenosis. This imbalance may represent selection 
bias, whereby patients with more severe stroke and 
severe stenosis were not imaged as doing so would not 
change management. It is unclear whether there are 
drug class-specific mechanisms that may be harmful 
in the context of carotid stenosis early after stroke, 
but we add to evidence from the main ENOS Trial 
that routinely continuing prestroke antihypertensives 
should perhaps be avoided until the patient is neuro-
logically stable.7 Whether larger precipitous drops in 
BP are safe is beyond the scope of this substudy, but 
given the uncertainty this practice should perhaps be 
avoided.
The shift in mRS to less death or dependency with 
GTN seen in those with ≥70% ipsilateral carotid stenosis 
may be related to effects other than BP lowering. As a 
vasodilator, GTN did not reduce cerebral blood flow in 
patients with acute stroke despite lowering peripheral 
and central BP.27 28 Although it is unclear whether GTN 
improves cerebral blood flow,28 it can be hypothesised 
that GTN may improve collateral blood supply via surface 
pial collaterals29 and thereby maintain blood flow to the 
ischaemic penumbra in the context of carotid stenosis 
when given early. A similar potential beneficial effect of 
transdermal GTN administered within 4 hours of stroke 
onset in patients with ≥70% ipsilateral carotid stenosis 
was seen in a preliminary analysis of 314 patients from 
the Rapid Intervention with Glyceryl trinitrate in Hyper-
tensive stroke Trial-2 (RIGHT-2).30
Bilateral carotid stenosis is uncommon (4.8% in this 
analysis) and therefore data regarding the safety of BP 
lowering in patients with acute stroke in this context are 
scanty.6 Impaired cerebral perfusion is more common in 
this population than in unilateral carotid stenosis and 
although we found no evidence that modest BP lowering 
was unsafe, further data are required to address this 
question.
This study represents the largest trial-based anal-
ysis of BP lowering in patients with acute ischaemic 
stroke with carotid stenosis to date. However, there 
are limitations. First, not all patients with ischaemic 
stroke had carotid imaging studies performed, a defi-
ciency most prominent in patients with severe stroke 
who would not be appropriate candidates for revascu-
larisation therapy. Second, the analyses across degrees 
of carotid stenosis are subgroup analyses and, so the 
results may represent chance. Third, the median time 
to randomisation in ENOS was 26 hours and so the 
effect of BP lowering in the context of carotid stenosis 
within the first few hours of ischaemic stroke remains 
unclear. Fourth, no adjustment was made for multi-
plicity of testing due to the exploratory nature of the 
study. Fifth, imaging information on carotid stenosis 
was provided by investigators at the site with unknown 
reporting criteria (NASCET,13 European Carotid 
Surgery Trial [ECST]),31 and Carotid and Vertebral 
Artery Transluminal Angioplasty Study (CAVATAS)32) 
and were not centrally adjudicated. However, data 
were validated and checked for accuracy. Sixth, it 
was not possible to adjust cognitive outcome data 
for cognition at baseline and many of the differ-
ences seen at 3 months in association with degrees of 
stenosis (apart from allocated trial treatment differ-
ences) likely reflect baseline status. Seventh, ENOS 
assessed mild to moderate BP lowering and the results 
presented here do not provide information on the 
effects of intensive BP lowering. Last, data on carotid 
endarterectomy were not captured prospectively in 
ENOS and were therefore unavailable for the popu-
lation studied, although in a population of patients 
with mostly moderate-to-severe stroke it is unlikely 
that many patients underwent endarterectomy.
In summary, this ENOS substudy has demonstrated that 
severe ipsilateral carotid stenosis is associated with worse 
clinical outcomes at 7 days and 90 days after acute stroke 
irrespective of treatment allocation. Transdermal GTN 
improved functional outcome at 90 days in those with 
≥70% ipsilateral stenosis and was safe across all degrees of 
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carotid stenosis whether unilateral or bilateral. Further, 
modest BP lowering with GTN was safe in the context of 
carotid stenosis although continuing prestroke antihyper-
tensives was associated with poorer secondary outcomes 
in those with 50–<70% ipsilateral carotid stenosis. Future 
studies should establish whether GTN and other BP 
lowering therapies have specific mechanistic properties 
that may be of benefit in acute stroke in the context of 
carotid stenosis.
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